Health
“A pooled analysis of studies involving more than 430,000 people found that every two cups of coffee consumed per day was associated with a 44% lower risk of liver cirrhosis." (Instagram, @drjoshaxe, posted 2026-11-09)”
Plain restatementA meta-analysis of observational studies with a combined sample above 430,000 participants reported that each additional two cups of coffee per day was associated with approximately 44% lower relative risk of liver cirrhosis.
General information only - not medical advice.
This claim checks out on the numbers. A 2016 meta-analysis published in Alimentary Pharmacology and Therapeutics pooled nine studies covering 432,133 people and found that each extra two cups of coffee per day was linked to a 44% lower relative risk of liver cirrhosis. The post is careful to say "associated with," which is the right word, because every study in that analysis was observational and none could prove coffee causes the benefit. Two important pieces of context are missing from the post. First, the individual studies disagreed a lot with each other, coffee intake was self-reported, and the authors themselves stopped short of telling people to drink more coffee. Second, the 44% figure is about cirrhosis, which is advanced liver scarring often driven by alcohol or hepatitis, while the post uses it inside a message about fatty liver disease, a different condition. A large 2024 cohort reanalysis also suggests earlier studies may have overstated coffee's liver benefit once confounding factors were better handled. General information only, not medical advice, and anyone with liver concerns should talk to a clinician rather than change habits based on a social media clip.
A [drifted from the evidence:] pooled analysis of studies [drifted from the evidence:] involving more than 430,000 [drifted from the evidence:] people found that [drifted from the evidence:] every two cups of coffee [drifted from the evidence:] consumed per day was associated with [drifted from the evidence:] a 44% lower risk of liver cirrhosis." [drifted from the evidence:] (Instagram, @drjoshaxe, posted 2026-11-09)
A [added by the neutral restatement:] meta-analysis of [added by the neutral restatement:] observational studies [added by the neutral restatement:] with a combined sample above 430,000 [added by the neutral restatement:] participants reported that [added by the neutral restatement:] each additional two cups of coffee per day was associated with [added by the neutral restatement:] approximately 44% lower [added by the neutral restatement:] relative risk of liver cirrhosis.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- A pooled analysis (meta-analysis) with this finding exists and is identifiable: Kennedy et al., Aliment Pharmacol Ther, 2016.
- The participant figure is accurate: 432,133 people, which is "more than 430,000."
- The effect size is accurately converted: pooled RR 0.56 equals a 44% lower relative risk.
- The exposure framing is accurate: the estimate was specifically calculated per two-cup daily increase in coffee consumption.
- The outcome is accurately named: liver cirrhosis.
- The word "associated" is used correctly. The post does not claim coffee causes a reduction in cirrhosis.
- A dose-response relationship was observed in most of the included studies, so the general direction of the post's message is consistent with the source.
- Omitted qualifier (evidence quality): the post presents a clean headline number without noting that all nine inputs were observational studies with self-reported coffee intake, and that heterogeneity was very high (I2 83.3%). The confidence interval ranged from a 32% to a 56% reduction, not a fixed 44%.
- Omitted qualifier (causation boundary): although "associated with" is technically correct, the surrounding transcript uses the finding as practical advice about what to drink to protect your liver, which implies a causal benefit the study design cannot establish. Guideline bodies describe the coffee-liver relationship as observational and note that interventional evidence is scarce.
- Context mismatch (outcome swap): the caption and surrounding content are about fatty liver disease, while the cited 44% figure is about cirrhosis. Much of the signal in the underlying literature comes from alcohol-related cirrhosis. The meta-analysis separately reported alcoholic cirrhosis at RR 0.62. Applying a cirrhosis number to a fatty liver message blurs two different outcomes.
- Framing beyond the source: the transcript's emphasis on black coffee versus sweetened coffee drinks is a reasonable general point, but the meta-analysis did not compare black coffee against sweetened coffee drinks. That distinction is the presenter's addition, not a study finding.
- Missing authors' own restraint: contemporaneous reporting noted that in the discussion the researchers stopped short of recommending an increase in coffee consumption, writing that the wider effects need to be considered.
- The full text of the 2016 paper, including its GRADE rating for the cirrhosis outcome and its complete risk-of-bias table, was not retrieved directly. The same research group rated the evidence for the closely related coffee and liver cancer question as "very low" under GRADE, downgraded for risk of bias, indirectness and publication bias, but that rating belongs to the hepatocellular carcinoma paper, not verified here for the cirrhosis paper.
- Whether the association is causal remains unresolved. A 2024 large cohort analysis using IPTW adjustment found that after adjustment only all-cause mortality significantly decreased, and suggested earlier studies may have overestimated coffee's favorable effect on chronic liver disease.
- The absolute risk reduction for an individual is not stated in the claim and was not retrieved. A 44% relative reduction means very different things for a person with heavy alcohol use or chronic hepatitis than for a low-risk person.
- Whether the specific Instagram post makes further unverified claims beyond this sentence could not be assessed, since only the transcript excerpt and caption were available at intake.
The numbers in the post trace to a real and identifiable study. Kennedy and colleagues identified five cohort studies and four case-control studies involving 1990 cases and 432,133 participants, and the pooled RR of cirrhosis for a daily increase in coffee consumption of two cups was 0.56 (95% CI 0.44-0.68; I2 83.3%). A relative risk of 0.56 corresponds to a 44% lower relative risk, and 432,133 is "more than 430,000." The RR pooled from cohort studies for a daily increase of two cups was 0.58 (95% CI 0.41-0.76; I2 91.1%) and from case-control studies it was 0.52 (95% CI 0.40-0.63; I2 0.0%). The pooled RR of alcoholic cirrhosis for a daily increase of two cups was 0.62 (95% CI 0.51-0.73; I2 0%) and of death from cirrhosis it was 0.55 (95% CI 0.35-0.74; I2 90.3%). The authors concluded that the meta-analysis "suggests that increasing coffee consumption may substantially reduce the risk of cirrhosis." The underlying relationship was modelled as a dose-response gradient rather than a single two-cup threshold. In eight of the nine studies examined, increasing coffee consumption by two cups per day was associated with a statistically significant reduction in cirrhosis risk, and the lead author told CNN that compared to no coffee, one cup per day was associated with a 22% lower risk and four cups per day with a 65% lower risk. Context from the clinical guideline literature is more cautious than the post. The EASL-EASD-EASO MASLD guideline states that in adults with MASLD, coffee consumption has been associated with improvements in liver damage and reduced liver-related clinical outcomes in observational studies, and notes that interventional data on hepatic effects of coffee consumption are scarce. A 2024 cohort reanalysis found that after inverse probability of treatment weighting adjustment, only all-cause mortality significantly decreased, suggesting previous studies might have overestimated the favorable effect of coffee intake on chronic liver disease due to confounding factors.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Is the 44% lower cirrhosis risk figure real?
Yes. It comes from a 2016 meta-analysis by Kennedy and colleagues that pooled nine studies covering 432,133 people, and found a 44% lower relative risk of cirrhosis for every two additional cups of coffee consumed per day.
Does this mean coffee prevents cirrhosis?
The investigation did not establish that. All nine studies in the meta-analysis were observational, coffee intake was self-reported, and the researchers themselves stopped short of recommending people drink more coffee.
Why does the summary say the post mixes up two different liver conditions?
The 44% figure applies to cirrhosis, which is advanced liver scarring often linked to alcohol or hepatitis, but the post uses it in a message about fatty liver disease, a different condition. The meta-analysis also found a separate, somewhat different effect specifically for alcoholic cirrhosis.
Does newer research change the picture?
A 2024 cohort reanalysis using more rigorous adjustment for confounding factors found that only all-cause mortality significantly decreased, suggesting earlier studies may have overstated coffee's benefit for chronic liver disease.
Does the claim about black coffee versus sweetened coffee drinks come from this study?
No. The meta-analysis did not compare black coffee to sweetened coffee drinks. That distinction was added by the presenter and is not a finding from the cited research.